Please wait a minute...
文章检索
预防医学  2025, Vol. 37 Issue (12): 1206-1210,1216    DOI: 10.19485/j.cnki.issn2096-5087.2025.12.004
  论著 本期目录 | 过刊浏览 | 高级检索 |
2005—2024年衢州市30岁以下人群乙型病毒性肝炎发病趋势及年龄-时期-队列分析
郑灿杰1, 尹志英1, 何寒青2, 周洋2
1.衢州市疾病预防控制中心,浙江 衢州 324000;
2.浙江省疾病预防控制中心,浙江 杭州 310051
Incidence trend and age-period-cohort analysis of hepatitis B among people aged under 30 years in Quzhou City from 2005 to 2024
ZHENG Canjie1, YIN Zhiying1, HE Hanqing2, ZHOU Yang2
1. Quzhou Center for Disease Control and Prevention, Quzhou, Zhejiang 324000, China;
2. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China
全文: PDF(1123 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解2005—2024年浙江省衢州市<30岁人群乙型病毒性肝炎(乙肝)报告发病率变化趋势及年龄、时期和队列效应。方法 通过中国疾病预防控制信息系统传染病报告信息管理系统收集2005—2024年衢州市<30岁乙肝报告病例资料,计算乙肝报告发病率;采用平均年度变化百分比(AAPC)分析2005—2024年衢州市<30岁人群乙肝报告发病率变化趋势,采用年龄-时期-队列模型分析年龄、时期和出生队列对乙肝报告发病率的影响。结果 2005—2024年衢州市<30岁人群乙肝病例3 805例,年均报告发病率为31.61/10万;男性乙肝年均报告发病率为36.65/10万,高于女性的26.08/10万(P<0.05)。2005—2024年衢州市<30岁全人群、男性和女性乙肝报告发病率呈下降趋势(AAPC=-9.887%、-10.415%和-9.320%,均P<0.05)。年龄-时期-队列模型分析结果显示,2005—2024年衢州市<30岁全人群乙肝报告发病率随年龄增长呈先下降后上升趋势,从0~<5岁组的4.21/10万下降至10~<15岁组的2.07/10万,随后逐渐上升至25~<30岁组的22.49/10万;以2010—2014年为对照组,2005—2024年乙肝发病风险随时期推移呈下降趋势,RR值从2005—2009年的1.842(95%CI:1.433~2.366)下降至2020—2024年的0.446(95%CI:0.294~0.675);以2000—2004年出生队列为对照组,乙肝发病风险随出生年份推移呈下降趋势,1980—1984年出生队列的发病风险最高,RR值为4.731(95%CI:3.083~7.259)。男性和女性乙肝发病的年龄、时期和队列效应与全人群基本一致。结论 2005—2024年衢州市<30岁人群乙肝报告发病率总体呈下降趋势,随年龄增长呈先下降后上升趋势,乙肝发病风险随时期和出生年份推移呈下降趋势。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
郑灿杰
尹志英
何寒青
周洋
关键词 乙型病毒性肝炎发病率平均年度变化百分比年龄-时期-队列模型    
AbstractObjective To investigate the trend in reported incidence of hepatitis B and to assess the effects of age, period, and birth cohort among people aged <30 years in Quzhou City, Zhejiang Province from 2005 to 2024. Methods Reported cases of hepatitis B among people aged <30 years in Quzhou City from 2005 to 2024 were collected from the Infectious Disease Reporting Information System of Chinese Disease Prevention and Control Information System. The reported incidence was calculated. The average annual percent change (AAPC) was used to analyze the trend in reported incidence from 2005 to 2024. An age-period-cohort model was employed to analyze the effects of age, period, and birth cohort on the reported incidence of hepatitis B. Results From 2005 to 2024, a total of 3 805 hepatitis B cases were reported among people aged <30 years in Quzhou City, with an average annual reported incidence of 31.61/105. The average annual reported incidence of hepatitis B was higher in males than in females (36.65/105 vs. 26.08/105, P<0.05). From 2005 to 2024, the reported incidence of hepatitis B among the entire people aged <30 years, as well as among males and females separately in Quzhou City, showed declining trends (AAPC=-9.887%, -10.415%, and -9.320%, respectively, all P<0.05). The age-period-cohort model analysis revealed that the incidence first decreased and then increased with age, declining from 4.21/105 in the age group of 0-<5 years to 2.07/105 in the age group of 10-<15 years, before rising to 22.49/105 in the age group of 25-<30 years. Using the 2010-2014 period as the reference, the risk of hepatitis B showed a decreasing trend over time. The RR value decreased from 1.842 (95%CI: 1.433-2.366) for 2005-2009 to 0.446 (95%CI: 0.294-0.675) for 2020-2024. Using the 2000-2004 birth cohort as the reference, the risk showed a decreasing trend with more recent birth years. The highest risk was observed in the 1980-1984 birth cohort, with an RR value of 4.731 (95%CI: 3.083-7.259). The age, period, and cohort effects on the reported incidence of hepatitis B among males and females were generally consistent with those observed in the entire population. Conclusions From 2005 to 2024, the reported incidence of hepatitis B among people aged <30 years in Quzhou City showed a declining trend, while exhibiting a pattern of first decreasing and then increasing with age. Furthermore, the risk of hepatitis B incidence demonstrated a decreasing trend over both time periods and birth cohorts.
Key wordshepatitis B    incidence    average annual percent change    age-period-cohort model
收稿日期: 2025-08-20      修回日期: 2025-11-17      出版日期: 2025-12-10
中图分类号:  R512.6  
基金资助:2023年度中国乙肝防控科研基金项目(YGFK20230058,YGFK20230126); 2025年度免疫规划技术及相关政策应用研究课题(2025-B-05)
作者简介: 郑灿杰,硕士,副主任医师,主要从事疫苗针对性疾病监测与处置工作
通信作者: 周洋,E-mail:yzhou@cdc.zj.cn   
引用本文:   
郑灿杰, 尹志英, 何寒青, 周洋. 2005—2024年衢州市30岁以下人群乙型病毒性肝炎发病趋势及年龄-时期-队列分析[J]. 预防医学, 2025, 37(12): 1206-1210,1216.
ZHENG Canjie, YIN Zhiying, HE Hanqing, ZHOU Yang. Incidence trend and age-period-cohort analysis of hepatitis B among people aged under 30 years in Quzhou City from 2005 to 2024. Preventive Medicine, 2025, 37(12): 1206-1210,1216.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2025.12.004      或      http://www.zjyfyxzz.com/CN/Y2025/V37/I12/1206
[1] 周天天,张丹,王锐泽,等.2020年陕西省1~69岁人群乙型肝炎血清流行病学调查[J].中国疫苗和免疫,2023,29(2):164-168.
ZHOU T T,ZHANG D,WANG R Z,et al.A hepatitis B sero-epidemiological survey among 1-69-year-olds in Shaanxi Province, 2020[J].Chin J Vaccines Immun,2023,29(2):164-168.(in Chinese)
[2] CAO G Y,LIU J,LIU M.Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019:findings from the Global Burden of Disease Study[J].Chin Med J,2022,135(17):2049-2055.
[3] World Health Organization.Hepatitis B[EB/OL].[2025-11-17] .https://www.who.int/zh/news-room/fact-sheets/detail/Hepatitis-b.
[4] ZHENG H,WANG Y,WANG F Z,et al.New progress in HBV control and the cascade of health care for people living with HBV in China:evidence from the fourth national serological survey,2020[J/OL].Lancet Reg Health West Pac,2024,51[2025-11-17] .https://doi.org/10.1016/j.lanwpc.2024.101193.
[5] ZHANG J Y,LU Y B,LI H R,et al.Lip and oral cavity cancer burden and related risk factors in China:estimates and forecasts from1990 to 2049[J/OL].Healthcare (Basel),2022,10[2025-11-17] .https://doi.org/10.3390/healthcare10091611.
[6] ROSENBERG P S,CHECK D P,ANDERSON W F.A web tool for age-period-cohort analysis of cancer incidence and mortality rates[J].Cancer Epidemiol Biomarkers Prev,2014,23(11):2296-2302.
[7] 黄勇,王雯,张春焕,等.2005—2018年广州市乙型肝炎流行病学特征分析[J].疾病监测,2020,35(12):1120-1124.
HUANG Y,WANG W,ZHANG C H,et al.Epidemiological characteristics of hepatitis B in Guangzhou,2005-2018[J].Dis Surveill,2020,35(12):1120-1124.(in Chinese)
[8] 徐旭卿,林霞,曾蓓蓓,等.1991—2007年浙江省乙型病毒性肝炎报告发病特征分析[J].疾病监测,2010,25(4):263-266.
XU X Q,LIN X,ZENG B B,et al.Epidemiological analysis of viral hepatitis B in Zhejiang,1991-2007[J].Dis Surveill,2010,25(4):263-266.(in Chinese)
[9] 李傅冬,何凡,何寒清,等.2004—2020年浙江省10岁以下儿童乙型病毒性肝炎发病的年龄-时期-队列分析[J].预防医学,2024,36(9):737-740.
LI F D,HE F,HE H Q,et al.Age-period-cohort analysis of the incidence of hepatitis B among children aged under 10 years in Zhejiang Province from 2004 to 2020[J].China Prev Med J,2024,36(9):737-740.(in Chinese)
[10] FANG K,SHI Y Y,ZHAO Z Y,et al.Trends in disease burden of hepatitis B infection in Jiangsu Province,China,1990-2021[J].Infect Dis Model,2023,8(3):832-841.
[11] 万咏梅,王富珍,张国民,等.成人乙型肝炎感染风险和疾病负担[J].中国疫苗和免疫,2019,25(5):611-616.
WAN Y M,WANG F Z,ZHANG G M,et al.Risk and disease burden of adult hepatitis B infection[J].Chin J Vaccines Immun,2019,25(5):611-616.(in Chinese)
[12] 王富珍,郑徽,孙校金,等.中国控制乙型病毒性肝炎的成就与展望[J].中国疫苗和免疫,2019,25(5):487-492.
WANG F Z,ZHENG H,SUN X J,et al.Achievements and prospects for hepatitis B prevention and control in China[J].Chin J Vaccines Immun,2019,25(5):487-492.(in Chinese)
[13] 国家卫生健康委员会.国家免疫规划疫苗儿童免疫程序及说明(2021年版)[J].中国病毒病杂志,2021,11(4):241-245.
National Health Commission of the People's Republic of China.Program and description of national immunization program vaccine for children(2021 edition)[J].Chin J Viral Dis,2021,11(4):241-245.(in Chinese)
[1] 杜昌翰, 高琳茜, 卢心雨, 赵渭娟, 李领. 1992—2021年我国老年人群口腔癌疾病负担的年龄-时期-队列分析[J]. 预防医学, 2025, 37(9): 870-874.
[2] 李玉荣, 王冬飞, 高媛媛, 蒋园园, 林君英, 肖段段. 2010—2024年萧山区结直肠癌发病趋势分析[J]. 预防医学, 2025, 37(9): 927-931,936.
[3] 李君, 朱婷婷, 胡文雪. 2005—2023年温州市丙型病毒性肝炎流行特征分析[J]. 预防医学, 2025, 37(9): 932-936.
[4] 胡晓强, 刘艳, 周思凡, 张子喆, 王雨达, 沈建勇. 2014—2023年湖州市流行性感冒流行特征分析[J]. 预防医学, 2025, 37(9): 959-962.
[5] 李克, 庞志峰, 吴晓虹, 王诚, 何瑶, 唐慧玲. 2007—2024年金华市钩端螺旋体病流行特征分析[J]. 预防医学, 2025, 37(8): 818-821.
[6] 冷雪, 傅淑琴, 舒纪为, 谭启龙, 李科峰. 舟山市带状疱疹首诊病例特征分析[J]. 预防医学, 2025, 37(7): 701-704.
[7] 朱颖, 郑添. 2013—2023年嘉善县居民期望寿命变化[J]. 预防医学, 2025, 37(6): 598-602.
[8] 董沙沙, 项云飞. 2014—2023年余姚市原发性肝癌死亡与疾病负担分析[J]. 预防医学, 2025, 37(6): 603-607.
[9] 丁哲渊, 杨研, 傅天颖, 鲁琴宝, 王心怡, 吴昊澄, 刘魁, 林君芬, 吴晨. 2024年浙江省法定传染病疫情分析[J]. 预防医学, 2025, 37(5): 433-438,442.
[10] 任露露, 顾嘉昌, 闵艺璇, 张思晨, 乔健健, 肖月, 胡静. 2016—2023年宜兴市脑卒中发病趋势分析[J]. 预防医学, 2025, 37(5): 498-502.
[11] 李慧君, 叶振淼, 樊丽辉, 郑宇航, 谢轶敏, 姜雪霞, 高豪俊, 张默涵, 罗永园. 2015—2023年温州市老年人跌倒死亡趋势与减寿分析[J]. 预防医学, 2025, 37(5): 460-464.
[12] 周沁易, 马涛, 赵跃媛, 王恒学, 吴小清, 丁松宁, 苏晶晶. 2004—2022年南京市法定传染病发病趋势分析[J]. 预防医学, 2025, 37(5): 476-480.
[13] 白峻竹, 比里克孜汉·阿西木, 游姝萌, 阿米乃·艾比, 金雅静, 徐元勇, 温亮, 张文义, 买买提江·吾布力艾山. 2016—2022年和田地区乙型病毒性肝炎和丙型病毒性肝炎流行特征分析[J]. 预防医学, 2025, 37(4): 404-407,412.
[14] 王洪岩, 任飞林, 刘小琦, 金玫华, 吴振乾. 2009—2023年湖州市HIV/AIDS病例新发现率趋势分析[J]. 预防医学, 2025, 37(4): 395-399.
[15] 叶振淼, 樊丽辉, 姜雪霞, 郑宇航, 张默涵, 罗永园, 谢轶敏, 李慧君, 金茜. 2014—2023年温州市胃癌死亡及减寿趋势分析[J]. 预防医学, 2025, 37(3): 267-271.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed